These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 8184174

  • 1. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R.
    Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
    [Abstract] [Full Text] [Related]

  • 2. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
    Harinarayan CV.
    J Indian Med Assoc; 2004 May; 102(5):258, 260-1. PubMed ID: 15636029
    [Abstract] [Full Text] [Related]

  • 7. Medical management of acromegaly--what and when?
    Melmed S.
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
    [Abstract] [Full Text] [Related]

  • 8. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U, Quabbe HJ.
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [Abstract] [Full Text] [Related]

  • 9. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
    Barakat S, Melmed S.
    Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
    [Abstract] [Full Text] [Related]

  • 10. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N, Mészáros J, Czirják S, Mondok A, Varga I, Gláz E.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [Abstract] [Full Text] [Related]

  • 11. Medical management of acromegaly: effects of SMS 201-995 in 30 patients.
    Pagani G, Montini M, Gianola D, Pagani MD, Tengattini F, Dominoni P, Ghilardi G, Cortesi L, Pedroncelli A, Tonnarelli GP.
    Endocrinol Exp; 1990 Mar 12; 24(1-2):175-85. PubMed ID: 2361459
    [Abstract] [Full Text] [Related]

  • 12. Evidence supporting surgery as treatment of choice for acromegaly.
    Fahlbusch R, Honegger J, Buchfelder M.
    J Endocrinol; 1997 Oct 12; 155 Suppl 1():S53-5. PubMed ID: 9389996
    [Abstract] [Full Text] [Related]

  • 13. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE, Thornton-Jones VA, Wass JA.
    Clin Endocrinol (Oxf); 2004 Aug 12; 61(2):224-31. PubMed ID: 15272918
    [Abstract] [Full Text] [Related]

  • 14. Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study.
    Bogazzi F, Di Bello V, Palagi C, Donne MG, Di Cori A, Gavioli S, Talini E, Cosci C, Sardella C, Brogioni S, Mariani M, Martino E.
    Clin Endocrinol (Oxf); 2005 May 12; 62(5):590-6. PubMed ID: 15853830
    [Abstract] [Full Text] [Related]

  • 15. The efficacy of octreotide LAR as firstline therapy for patients with newly diagnosed acromegaly is independent of tumor extension: predictive factors of tumor and biochemical response.
    Luque-Ramírez M, Portoles GR, Varela C, Albero R, Halperin I, Moreiro J, Soto A, Casamitjana R, Spanish Multicentre Group for the Study of Acromegaly.
    Horm Metab Res; 2010 Jan 12; 42(1):38-44. PubMed ID: 19798622
    [Abstract] [Full Text] [Related]

  • 16. Treatment outcomes and mortality of 94 patients with acromegaly.
    Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P, Christ ER.
    Acta Neurochir (Wien); 2005 Mar 12; 147(3):243-51; discussion 250-1. PubMed ID: 15627919
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
    Gradiser M, Matovinovic M, Vrkljan M.
    Croat Med J; 2007 Feb 12; 48(1):87-91. PubMed ID: 17309144
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.